|
|
|
|
|
|
| Abstract Search | Browse Program and Abstracts | Schedule-at-a-Glance | Conference Mission & Sponsors | Program Committee | Contact Us |
| # | Title |
|---|---|
| 113 | Inhibition of sCD4-Induced Conformational Changes of gp41 Ectodomain by C Peptide
L. Yi, L. Hong, and T Hattori* Graduate Sch. of Med., Tohoku Univ., Sendai, Japan |
| 114 | Residues of GP120 Core Structure on the GP41 Interacting Face Contributing to the High Neutralization Resistance of Wild-Type Strains of HIV-1: Relevance to Vaccine Development
M. Leavitt*, E.-J. Park, and G. Quinnan Uniformed Services Univ. of the Hlth. Sci., Bethesda, MD, USA |
| 115 | Membrane Permeabilization by the HIV-1 gp41 Cytoplasmic LLP Domains Differs by Subtype
W. Dowling*1, M. Robb1, D. Birx1, and F. McCutchan2 1Walter Reed Army Inst. of Res., Washington, DC, USA and 2Henry M. Jackson Fndn., Rockville, MD, USA |
| 116 | In Vivo Alteration of the Highly Conserved 370 Residue of Human Immunodeficiency Virus Type 1 gp120 Determines Neutralization Sensitivity against CD4-Bnding Site and gp41-Directed Agents
T. Beaumont*1, A. van Nuenen1, S. Broersen1, D. Schols2, and H. Schuitemaker1 1CLB Sanquin and Univ. of Amsterdam, The Netherlands and 2Rega Inst. for Med. Res., Leuven, Belgium |
| 117 | A Chimeric Protein of SIV Envelope Glycoprotein Gp-160e and E. coli Aspartate Transcarbamoylase
B. Chen*1, J.J. Skehel3, E.L. Reinherz4, S.C. Harrison1,2, and D.C. Wiley1,2 1The Children's Hosp./Harvard Univ., Boston, MA, USA; 2 Howard Hughes Med. Inst., Boston, MA, USA; 3Natl. Inst. for Med. Res., London, UK; and 4Dana Farber Cancer Inst., Boston, MA, USA |
| 118 | Structural Flexibility and Functional Valency of CD4-IgG2 (PRO 542) and CD4- K. H. Roux*1, Z. Ping1, and W. C. Olson2 1Florida State Univ., Tallahassee, USA and 2Progenics Pharma., Inc., Tarrytown, NY, USA |
| 119 | Selective Mutations of the gp120 Glycosylations Sites on an Acute HIV-1 Infection Primary Isolate env Sequence According to their Clustering on the 3D Model
F. Bedin, Y. Ataman-Önal, F. Reynard, P.-Y. Durand, M. Girard, and B. Verrier* CNRS-BioMerieux, CERVI, Lyon, France |
| 120 | Structural Features of HIV Envelope Defined by Antibody Escape Mutant Analysis
S. D’Costa*1, K. S. Slobod1, R. G. Webster1, S. White1, and J. Hurwitz1,2 1St Jude Children’s Res. Hosp., Memphis, TN, USA and 2Univ. of Tennessee, Memphis, USA |
| 121 | Effects of Glycosylation Variation on Envelope-Specific Antibody Responses
K. S. Cole*1, J. D. Steckbeck 1, J. L. Rowles1, R. C. Desrosiers2, and R. C. Montelaro1 1Univ. of Pittsburgh Sch. of Med., PA, USA and 2New England Regional Primate Res. Ctr., Southborough, MA, USA |
| 122 | Chemically Inactivated HIV/SIV Virions with Functional Envelope Glycoproteins: In Vitro Applications
J. L. Rossio*1, M. Piatak, Jr.1, I. Frank2, M. Larsson2, N. Romani3, L. Henderson1, L. Arthur1, N. Bhardwaj2, M. Pope2, and J. D. Lifson1 1AVP, SAIC Frederick, NCI at Frederick, MD, USA; 2Rockefeller Univ., New York, NY, USA; and 3Univ. of Innsbruck, Austria |
| 123 | Selected Mutations to Remove the Potential N-Linked Glycosylation Sites at the V1-Loop of HIV-1 Envelope Glycoprotein Were Able to Induce Neutralizing Antibody Responses against the Primary HIV Isolate
S. Wang, I. Mboudjeka, S. Shen, T. Wu-Chou, T. Giehl, J. Brinker, and S. Lu* Univ. of Massachusetts Med. Sch., Worcester, USA |
| 124 | Production, Characterization, and Oligomeric Stabilization of Recombinant Disulfide Linked (SOS) HIV-1 Envelope Glycoproteins
N. Schülke*1, M. Vesanen2, R. Sanders2, A. Villa1, D. Anselma1, J. Binley3, P. Maddon1, J. Moore2, and W. Olson1 1Progenics Pharmaceuticals Inc., Tarrytown, NY, USA; 2Weill Med. Coll., Cornell Univ., New York, NY, USA; and 3The Scripps Res. Inst., La Jolla, CA, USA |
| 125 | Identification of a Fusion Intermediate Conformation of Soluble HIV Envelope gp41
M. Alam*1, H.-X. Liao1, C. Paleos1, S. Stauffer1, R. Scearce1, P. Ear2, and B. Haynes1 1Duke Med. Ctr., Durham, NC, USA and 2 NIAID, NIH, Bethesda, MD, USA |
| 126 | Combination of Monophosphoryl Lipid A and GM-CSF Adjuvant with an HIV Envelope Immunogen Coupled to a2-Macroglobulin Dramatically Increases HIV Envelope Subunit Immunogenicity
H.-X. Liao*, G. J. Ciancioloý, H. F. Staats, R. M. Scearce, D. M. Lapple, S. Stauffer, J. R. Thomasch, S. V. Pizzoý, D. C. Montefiori, and B. F. Haynes Duke Univ. Med. Ctr., Durham, NC, USA |
| 127 | Mapping of the Epitopes on HIV-1 gp120 Recognized by Neutralizing Human Monoclonal Antibodies by Alanine-Scanning Mutagenesis
R. Pantophlet*, E. Ollmann Saphire, I. A. Wilson, P. W. H. I. Parren, and D. R. Burton The Scripps Res. Inst., La Jolla, CA, USA |
| 128 | Immunogenicity of Conjugated HIV Gp120 and Env 2-3 in Mice
L. C. Paoletti*1 and R. C. Kennedy2 1Brigham & Women’s Hosp., Harvard Med. Sch, Boston, MA, USA and 2Texas Tech Univ. Hlth. Sci. Ctr., Lubbock, TX, USA |
| 129 | Effect of Variable Loop Deletion on Envelope Glycoprotein-Specific Cellular Responses and Protection against Challenge with Recombinant Vaccinia Virus Expressing gp160 of Primary HIV-1 Isolates
J. Gzyl*, I. Kiszka, D. Kmieciak, E. Bolesta, T. Naito, and D. Kozbor Temple Univ., Philadelphia, PA, USA |